Here is some news about AZTR:
- Presentation at the 2024 BIO International Convention: Azitra, Inc. (NYSE American: AZTR) will present at the 2024 BIO International Convention being held June 3-6, 2024, in San Diego, California. The presentation will highlight Azitra’s updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity1.
- Positive Preclinical Data of ATR-12: Azitra announced positive preclinical data of ATR-12 and clinical design in Netherton syndrome presented at the ASGCT Annual Meeting. ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndrome. Topical application of ATR-12 to ex vivo human skin results in superior LEKTI delivery compared to topical LEKTI application. ATR-12 reduces IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome. It is safe and well tolerated in minipigs23.
- Q1 2024 Financial Results and Business Updates: Azitra reported financial results for the three months ended March 31, 2024, and provided a business update. The company advanced ATR-12's Phase 1b trial, activating sites, and identifying initial subjects with Netherton syndrome for dosing. They successfully completed a pre-IND meeting with the FDA for ATR-04 and announced new preclinical data at ASGCT related to ATR-12. Azitra also completed a follow-on public offering, raising $5.0 million in gross proceeds4.
In conclusion, Azitra is making significant strides in the development of its pipeline, including positive preclinical data for ATR-12 and advancing its clinical trial plans. The company's presentation at the 2024 BIO International Convention and ongoing discussions with Bayer for a license agreement reflect the growing interest and potential of its innovative therapies for precision dermatology12.
6/17/2024 07:15pm
